var data={"title":"Ropivacaine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ropivacaine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6924?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ropivacaine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ropivacaine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=ropivacaine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ropivacaine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219215\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Naropin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219216\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Naropin;</li>\n      <li>Ropivacaine Hydrochloride Injection, USP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219245\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Local Anesthetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219219\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Dose varies with procedure, onset and depth of anesthesia desired, vascularity of tissues, duration of anesthesia, and condition of patient: A test dose of short-acting local anesthestic containing epinephrine (eg, 3 to 5 mL) should be administered prior to induction of complete block with ropivacaine. Incremental ropivacaine dosing is recommended.  Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">Surgical anesthesia: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lumbar epidural block for surgery:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">15 to 30 <b>mL</b> of 0.5% solution</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">15 to 25 <b>mL</b> of 0.75% solution </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">15 to 20 <b>mL</b> of 1% solution</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lumbar epidural block for cesarean section: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">20 to 30 <b>mL</b> dose of 0.5% solution </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">15 to 20 <b>mL</b> dose of 0.75% solution </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Thoracic epidural block: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">5 to 15 <b>mL</b> dose of 0.5% solution </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">5 to 15 <b>mL</b> dose of 0.75% solution</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Major nerve block: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">35 to 50 <b>mL</b> dose of 0.5% solution</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">10 to 40 <b>mL</b> dose of 0.75% solution</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Field block: 1 to 40 <b>mL</b> dose of 0.5% solution</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Labor pain management: Lumbar epidural: Initial: 10 to 20 <b>mL</b> 0.2% solution; continuous infusion dose: 6 to 14 <b>mL</b>/hour of 0.2% solution with incremental injections of 10 to 15 <b>mL</b>/hour of 0.2% solution </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Postoperative pain management: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peripheral nerve block: Continuous infusion dose: 5 to 10 <b>mL</b>/hour of 0.2% solution (Bagry, 2008; Klein, 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lumbar or thoracic epidural: Continuous infusion dose: 6 to 14 <b>mL</b>/hour of 0.2% solution </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infiltration/minor nerve block: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">1 to 100 <b>mL</b> dose of 0.2% solution </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">1 to 40 <b>mL</b> dose of 0.5% solution</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219220\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Use with caution; initial dose reductions may be necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22553469\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. However, ropivacaine and its metabolites are renally excreted, and the risk of toxic reactions may be greater.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22553470\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use with caution; ropivacaine undergoes hepatic metabolism and patients may be at a greater risk for developing toxic drug levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219198\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Epidural, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5% (100 mL); 0.1% in NaCl 0.9% (200 mL); 0.15% in NaCl 0.9% (100 mL); 0.2% in NaCl 0.9% (100 mL, 250 mL, 400 mL, 500 mL); 0.25% in NaCl 0.9% (150 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/mL (300 mL); 0.1% in NaCl 0.9% (100 mL, 250 mL, 400 mL, 550 mL, 600 mL); 0.2% in NaCl 0.9% (100 mL, 250 mL, 400 mL, 500 mL, 550 mL, 650 mL, 750 mL); 0.25% in NaCl 0.9% (400 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Naropin: 2 mg/mL (10 mL, 20 mL, 100 mL, 200 mL); 5 mg/mL (20 mL, 30 mL, 100 mL [DSC], 200 mL); 7.5 mg/mL (20 mL); 10 mg/mL (10 mL, 20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/mL (10 mL, 20 mL, 100 mL); 5 mg/mL (20 mL, 30 mL); 7.5 mg/mL (20 mL); 10 mg/mL (10 mL, 20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Epidural, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.2% in NaCl 0.9% (10 mL, 60 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219185\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219200\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administered via local infiltration, epidural block and epidural infusion, or intermittent bolus. Prior to ropivacaine administration, a test dose of short-acting local anesthestic with epinephrine (eg, 3 to 5 mL) should be administered. Incremental ropivacaine dosing is recommended. Do not administer large volume of anesthetic rapidly. The On-Q infusion pump is used to slowly administer local anesthetics (eg, bupivacaine, lidocaine, ropivacaine) to or around surgical wound sites and/or in close proximity to nerves for pre- or postoperative regional anesthesia. When infused directly into the shoulder, destruction of articular cartilage (chondrolysis) has occurred. On-Q pumps should never be placed directly into any joint (see https://www.ismp.org/Newsletters/acutecare/archives/May09.asp).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219199\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute pain management:</b> For acute pain management administered as an epidural continuous infusion, intermittent bolus (eg, postoperative or labor), or local infiltration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical anesthesia:</b> For the production of local or regional anesthesia for surgery administered as an epidural block, including cesarean section, major nerve block, or local infiltration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219253\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ropivacaine may be confused with bupivacaine, rOPINIRole</p>\n        <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Infusion bottles of Naropin (ropivacaine) and Ofirmev (acetaminophen) look similar. Potentially fatal mix-ups have been reported in which a glass bottle of Naropin was mistaken for Ofirmev in perioperative areas.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219192\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (dose-related and age-related: 32% to 69%), bradycardia (6% to 20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (11% to 29%), vomiting (7% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (7% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (1% to 5%), hypertension, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (5% to 8%), paresthesia (2% to 6%), dizziness (3%), chills (2% to 3%), anxiety (1%), hypoesthesia, rigors, shivering</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypokalemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Oral paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary retention (1% to 5%), urinary tract infection (1% to 5%), oliguria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (3% to 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Angioedema, apnea (usually associated with epidural block in head/neck region), bronchospasm, cardiac insufficiency, chondrolysis (continuous intra-articular administration), circulatory shock, dyskinesia, hallucination, hypersensitivity reaction, hyperthermia, laryngeal edema, myocardial infarction, seizure, skin rash, syncope, tinnitus, urticaria, ventricular arrhythmia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219203\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to ropivacaine, amide-type local anesthetics (eg, bupivacaine, mepivacaine, lidocaine), or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Intravenous regional anesthesia (Bier block); obstetric paracervical block anesthesia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219189\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS toxicity: Careful and constant monitoring of the patient's state of consciousness should be done following each local anesthetic injection; at such times, restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of CNS toxicity. Treatment is primarily symptomatic and supportive.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Intra-articular infusion related chondrolysis: Continuous intra-articular infusion of local anesthetics after arthroscopic or other surgical procedures is <b>not</b> an approved use; chondrolysis (primarily in the shoulder joint) has occurred following infusion, with some cases requiring arthroplasty or shoulder replacement.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with hypotension, hypovolemia, heart block, or cardiovascular disease; may be at greater risk for toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; may be at greater risk for toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurological disorders: Use with caution in patients with neurological disorders; may be at greater risk for toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Porphyria: Use with caution in patients with acute porphyria; consider use of alternative agents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Psychiatric disorders: Use with caution in patients with psychiatric disorders; may be at greater risk for toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment; may be at greater risk for toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Acutely ill patients: Use with caution in acutely ill;  may be at greater risk for toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Debilitated patients: Use with caution in debilitated patient; may be at greater risk for toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in the elderly: may be at greater risk for toxicity. Cardiovascular adverse events (bradycardia, hypotension) may be age-related (more common in patients &gt;61 years of age).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Rapid administration: Ropivacaine is not recommended for use in emergency situations where rapid administration is necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Trained personnel: Clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219240\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (major), CYP2B6 (minor), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219194\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9873&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bupivacaine (Liposomal): Local Anesthetics may enhance the adverse/toxic effect of Bupivacaine (Liposomal).  Management: Liposomal bupivacaine should not be administered with local anesthetics. Liposomal bupivacaine may be administered 20 minutes or more after the administration of lidocaine, but the optimal duration of dose separation for other local anesthetics is unknown<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): May increase the serum concentration of Ropivacaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FluvoxaMINE: May increase the serum concentration of Ropivacaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propofol: May increase the serum concentration of Ropivacaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept.  Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.  This interaction does not appear to apply to other uses of these agents in combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Management: Consider alternatives to such combinations whenever possible, particularly if the CYP1A2 substrate has a relatively narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219196\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219205\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. When used for epidural block during labor and delivery, systemically absorbed ropivacaine may cross the placenta, resulting in varying degrees of fetal or neonatal effects (eg, CNS or cardiovascular depression). Fetal or neonatal adverse events include fetal bradycardia (12%), neonatal jaundice (8%), low Apgar scores (3%), fetal distress (2%), neonatal respiratory disorder (3%). Maternal hypotension may also result from systemic absorption. In cases of hypotension, position pregnant woman in left lateral decubitus position to prevent aortocaval compression by the gravid uterus. Epidural anesthesia may prolong the second stage of labor. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20548418\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if ropivacaine is excreted into breast milk; however, exposure to a nursing infant is expected to be low. The manufacturer recommends that caution be exercised when administering ropivacaine to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3341407\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Heart rate, blood pressure, ECG monitoring (if used with antiarrhythmics)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219188\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219202\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Anesthesia (route dependent): 3 to 15 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration (dose and route dependent): 3 to 15 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Children: Epidural infusion: 2.1 to 4.2 L/kg (Hansen 2000)  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adults: Intravascular infusion: 41 &plusmn; 7 L </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic, via CYP1A2 to metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: Epidural: Terminal phase: 4.9 hours (range: 3 to 6.7 hours) (Hansen 2000) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Epidural: 5 to 7 hours; IV: Terminal: 111 &plusmn; 62 minutes (Lee, 1989)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Dose and route dependent: Caudal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants: Median: 60 minutes (range: 15 to 90 minutes) (Wulf 2000) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: Mean: 60 minutes (range: 12 to 249 minutes (Lonnqvist 2000) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (86% as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323799\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Naropin Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (100 mL): $46.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (30 mL): $26.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg/mL (20 mL): $22.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (20 mL): $27.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ropivacaine HCl (PF) Epidural)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (100 mL): $84.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ropivacaine HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (10 mL): $1.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (30 mL): $24.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg/mL (20 mL): $7.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (20 mL): $8.42</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ropivacaine HCl-NaCl (PF) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1-0.9% (400 mL): $77.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2-0.9% (550 mL): $222.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25-0.9% (400 mL): $176.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ropivacaine HCl-NaCl Epidural)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1-0.9% (200 mL): $40.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.15-0.9% (100 mL): $36.37</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2-0.9% (400 mL): $140.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25-0.9% (150 mL): $66.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Ropivacaine HCl-NaCl Epidural)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2-0.9% (10 mL): $8.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F219206\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anaropin (VN);</li>\n      <li>Narop (IL, SE);</li>\n      <li>Naropeine (FR, GR, PT, VN);</li>\n      <li>Naropin (AE, AR, AT, AU, BB, BE, BH, BM, BS, BZ, CH, CN, CO, CR, CY, CZ, DE, DK, DO, EG, ES, FI, GB, GT, GY, HK, HN, ID, IE, IQ, IR, IS, JM, JO, KR, KW, LB, LU, LY, MX, MY, NI, NL, NZ, OM, PA, PH, PL, QA, RO, RU, SA, SG, SI, SR, SV, SY, TH, TR, TT, UA, VE, YE);</li>\n      <li>Naropina (IT);</li>\n      <li>Ropibam (AU);</li>\n      <li>Ropica (TW);</li>\n      <li>Ropiva (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alahuhta S, Rasanen J, Jouppila P, et al, &ldquo;The Effects of Epidural Ropivacaine and Bupivacaine for Cesarean Section on Uteroplacental and Fetal Circulation,&rdquo; <i>Anesthesiology</i>, 1995, 83(1):23-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-drug-information/abstract-text/7605013/pubmed\" target=\"_blank\" id=\"7605013\">7605013</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bagry H, de la Cuadra Fontaine JC, Asenjo JF, et al, &quot;Effect of a Continuous Peripheral Nerve Block on the Inflammatory Response in Knee Arthroplasty,&quot; <i>Reg Anesth Pain Med</i>, 2008, 33(1):17-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-drug-information/abstract-text/18155052/pubmed\" target=\"_blank\" id=\"18155052\">18155052</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corcoran W, Butterworth J, Weller RS, et al, &quot;Local Anesthetic-Induced Cardiac Toxicity: A Survey of Contemporary Practice Strategies Among Academic Anesthesiology Departments,&quot; <i>Anesth Analg</i>, 2006, 103(5):1322-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-drug-information/abstract-text/17056977/pubmed\" target=\"_blank\" id=\"17056977\">17056977</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Datta S, Camann W, Bader A, et al, &ldquo;Clinical Effects and Maternal and Fetal Plasma Concentrations of Epidural Ropivacaine Versus Bupivacaine for Cesarean Section,&rdquo; <i>Anesthesiology</i>, 1995, 82(6):1346-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-drug-information/abstract-text/7793647/pubmed\" target=\"_blank\" id=\"7793647\">7793647</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dix SK, Rosner GF, Nayar M, et al, &ldquo;Intractable Cardiac Arrest Due to Lidocaine Toxicity Successfully Resuscitated With Lipid Emulsion,&rdquo; <i>Crit Care Med</i>, 2011, 39(4):872-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-drug-information/abstract-text/21263316/pubmed\" target=\"_blank\" id=\"21263316\">21263316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Foxall G, McCahon R, Lamb J, et al, &quot;Levobupivacaine-Induced Seizures and Cardiovascular Collapse Treated With Intralipid,&quot; <i>Anaesthesia</i>, 2007, 62(5):516-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-drug-information/abstract-text/17448066/pubmed\" target=\"_blank\" id=\"17448066\">17448066</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hansen TG, Ilett KF, Lim SI, et al, &ldquo;Pharmacokinetics and Clinical Efficacy of Long-Term Epidural Ropivacaine Infusion in Children,&rdquo; Br J Anaesth, 2000, 85(3):347-53.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hansen TG, Ilett KF, Reid C, et al, &ldquo;Caudal Ropivacaine in Infants: Population Pharmacokinetics and Plasma Concentrations,&rdquo; Anesthesiology, 2001, 94(4):579-84.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klein SM, Grant SA, Greengrass RA, et al, &quot;Interscalene Brachial Plexus Block With a Continuous Catheter Insertion System and a Disposable Infusion Pump,&quot; <i>Anesth Analg</i>, 2000, 91(6):1473-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-drug-information/abstract-text/11094003/pubmed\" target=\"_blank\" id=\"11094003\">11094003</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee A, Fagan D, Lamont M, et al, &ldquo;Disposition Kinetics of Ropivacaine in Humans,&rdquo; <i>Anesth Analg</i>, 1989, 69(6):736-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-drug-information/abstract-text/2589653/pubmed\" target=\"_blank\" id=\"2589653\">2589653</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Litz RJ, Popp M, Stehr SN, et al, &ldquo;Successful Resuscitation of a Patient With Ropivacaine-Induced Asystole After Axillary Plexus Block Using Lipid Infusion,&rdquo; <i>Anaesthesia</i>, 2006, 61(8):800-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-drug-information/abstract-text/16867094/pubmed\" target=\"_blank\" id=\"16867094\">16867094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lonnqvist PA, Westrin P, Larsson BA, et al, &ldquo;Ropivacaine Pharmacokinetics After Caudal Block in 1-8 Year Old Children,&rdquo; Br J Anaesth, 2000, 85(4):506-11.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McClure JH, &ldquo;Ropivacaine,&rdquo; <i>Br J Anaesth</i>, 1996, 76(2):300-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-drug-information/abstract-text/8777115/pubmed\" target=\"_blank\" id=\"8777115\">8777115</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirtallo JM, Dasta JF, Kleinschmidt KC, et al, &ldquo;State of the Art Review: Intravenous Fat Emulsions: Current Applications, Safety Profile, and Clinical Implications,&rdquo; <i>Ann Pharmacother</i>, 2010, 44(4):688-700.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-drug-information/abstract-text/20332339/pubmed\" target=\"_blank\" id=\"20332339\">20332339</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naropin (ropivacaine hydrochloride) [prescribing information]. Lake Zurich, IL: Fresenius Kabi USA, LLC; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naropin (ropivacaine) [product monograph]. Toronto, Ontario, Canada: Aspen Pharmacare Canada Inc; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenblatt MA, Abel M, Fischer GW, et al, &quot;Successful Use of a 20% Lipid Emulsion to Resuscitate a Patient After a Presumed Bupivacaine-Related Cardiac Arrest,&quot; <i>Anesthesiology</i>, 2006, 105(1):217-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-drug-information/abstract-text/16810015/pubmed\" target=\"_blank\" id=\"16810015\">16810015</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scott DB, Lee A, Fagan D, et al, &ldquo;Acute Toxicity of Ropivacaine Compared With That of Bupivacaine,&rdquo; <i>Anesth Analg</i>, 1989, 69(5):563-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-drug-information/abstract-text/2679230/pubmed\" target=\"_blank\" id=\"2679230\">2679230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simpson D, Curran MP, Oldfield V, et al, &ldquo;Ropivacaine. A Review of its Regional Anaesthesia and Acute Pain Management,&rdquo; <i>Drugs</i>, 2005, 65(18): 2675-2717.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wood MB and Rubin AP, &ldquo;A Comparison of Epidural 1% Ropivacaine and 0.75% Bupivacaine for Lower Abdominal Gynecologic Surgery,&rdquo; <i>Anesth Analg</i>, 1993, 76(6):1274-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-drug-information/abstract-text/8498665/pubmed\" target=\"_blank\" id=\"8498665\">8498665</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wulf H, Peters C, and Behnke H, &ldquo;The Pharmacokinetics of Caudal Ropivacaine 0.2% in Children. A Study of Infants Aged Less Than 1 Year and Toddlers Aged 1-5 Years Undergoing Inguinal Hernia Repair,&rdquo; Anaesthesia, 2000, 55(8):757-60.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zaric D, Axelsson K, Nydahl P, et al, &ldquo;Sensory and Motor Blockade During Epidural Analgesia With 1%, 0.75%, and 0.5% Ropivacaine - A Double-Blind Study,&rdquo; <i>Anesth Analg</i>, 1991, 72(4):509-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ropivacaine-drug-information/abstract-text/2006741/pubmed\" target=\"_blank\" id=\"2006741\">2006741</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9873 Version 147.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F219215\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F219216\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F219245\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F219219\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F219220\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22553469\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22553470\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F219198\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F219185\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F219200\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F219199\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F219253\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F219192\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F219203\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F219189\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F219240\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F219194\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F219196\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F219205\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20548418\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F3341407\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F219188\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F219202\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323799\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F219206\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9873|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ropivacaine-patient-drug-information\" class=\"drug drug_patient\">Ropivacaine: Patient drug information</a></li><li><a href=\"topic.htm?path=ropivacaine-pediatric-drug-information\" class=\"drug drug_pediatric\">Ropivacaine: Pediatric drug information</a></li></ul></div></div>","javascript":null}